Meanwhile, it has been confirmed that the PKM2 inhibitor shikonin can improve the resistance of tumor cells to cisplatin during bladder cancer treatment (Wang Y. et al., 2018). This evidence concerns the gene PKM and urinary bladder carcinoma.